An interventional study of blood sampling and stool collection in Smoking-related Pathology, Atheroma and Non-progressive Cancer > 5 Years, sponsored by Assistance Publique Hopitaux De Marseille. Recruiting at 1 site in France. Open to participants aged 45 Years to 80 Years. Per ClinicalTrials.gov, last updated 2026-11-10.
Sponsored by Assistance Publique Hopitaux De Marseille · Not applicable, Interventional, and Prevention
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 10 studies in Plaque, Atherosclerotic with a site in France — 5 open to participants now, 7 under way, 1 of them phase 3. Plaque, Atherosclerotic · France.
Among the 10 studies in Plaque, Atherosclerotic with a site in France, this one is one of 2 that started in 2024, is one of 4 with no phase, and was the 7th registered.
105 studies on the registry are indexed under Plaque, Atherosclerotic; 27 are open to participants now.
Browse Plaque, Atherosclerotic studies →5 of the 10 studies in Plaque, Atherosclerotic with a site in France are open now. Recruiting first, the newest first:
Hospices Civils de Lyon · Sites in France
Ages 18+
Centre Hospitalier Universitaire de Nīmes · Sites in France
Ages 18+
Elsan · Sites in France
Ages 40–80
GCS Ramsay Santé pour l'Enseignement et la Recherche · Sites in France
Ages 18+
A study can be open while its sites in France have not opened yet or have stopped. Only those recruiting at a site in France →
Of the 16 Plaque, Atherosclerotic studies recruiting now, 7 (44%) set no upper age limit and 4 (25%) stop at 75 or younger; none take children under 18; 1 takes healthy volunteers.
This study: 45 Years to 80 Years · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
10 studies; the count open now beside each. This study's row is marked.
First in 2005; this study’s year is marked. 2 started in 2024.
By drug class, each counting the studies that test any of its medicines:
This study's planned enrollment of 750 is above the median of 160 across 51 interventional studies indexed under Plaque, Atherosclerotic.
Median enrollment 385 across the 6 interventional studies, 100 across the 4 observational. Of the 3 that completed or were terminated, 1 (33%) have results posted.
This tab as a report to print or save as PDF → With an account.
2 of 10 have an industry lead sponsor. The 9 most frequent:
Assistance Publique Hopitaux De Marseille is the lead sponsor of 702 studies on the registry; 139 are open to participants now.
Assistance Publique Hopitaux De Marseille has 2 studies filed under Plaque, Atherosclerotic — fewer than ten, so there is no comparison to draw.
2 of the studies in Plaque, Atherosclerotic with a site in France that are under way reach primary completion within a year, 0 of them phase 3. Phase 3 first, then by date:
| Study | Primary completion |
|---|---|
| NCT06804707Hospices Civils de LyonCarotid Plaque Characterization Using Innovative Ultrasound Techniques | 2027-02-13 |
| NCT06226844Centre Hospitalier Universitaire de NīmesCan the BeatMove Device Help Patients With Obliterative Arterial Disease of the Lower Limbs? | 2027-11-01 |
Add all 2 to your calendar (.ics) → With an account.
Among the 10 studies in Plaque, Atherosclerotic with a site in France, from their registry updates:
This tab as a report to print or save as PDF → With an account.
Interventional study with minimal risks and constraints, with evaluation of the incidence of lung cancers by low-dose thoracic CT scan without injection of contrast medium, of the immunological, inflammatory and metabolic blood profile and of the microbiota; systematic proposal of smoking cessation for active smokers or assistance in maintaining cessation.
This study aims to validate candidate biomarkers associated with the risk of lung cancer diagnosis among patients with atheromatous disease associated with smoking.
hese candidate biomarkers were identified from blood and stool samples taken from the PREVALUNG cohort (NCT03976804), comprising 512 patients with at least one smoking-related atheromatous disease who underwent a thoracic CT lung cancer screening pathway (1 single screening round, i.e. one CT scan and one year of follow-up) at the Marie Lannelongue Hospital - Groupe Hospitalier Paris Saint-Joseph (Le Plessis-Robinson). This screening pathway led to the diagnosis of 14 patients (3%) with lung cancer, over 70% of whom were early-stage (I or II) and could be managed curatively by minimally invasive surgery (unpublished results, presented at the World Congress Lung cancer in Singapore on September 10 and 11, 2023). A case-control study nested in the PREVALUNG cohort compared the biological profiles of patients with suspected lung cancers or nodules with those of patients without lung nodules. Around 15,000 biomarkers per case and control were analyzed by standard statistical methods (descriptive and logistic regression), partial least square method and machine learning after reduction of the number of variables.
By analyzing several types of variables linked to inflammation, immunity, blood metabolomics and stool metagenomics, these analyses identified 14 biomarkers divided into 4 groups of candidate biomarkers associated with the diagnosis of lung cancers the second cohort, PREVALUNG ETOILE (NCT05649046), was recruited at Marseille's Hôpital Nord, using the same intervention methods as PREVALUNG, but extending the inclusion criteria to other tobacco-related diseases (atheroma, but also chronic bronchitis and tobacco-related cancers in remission for more than 5 years), to people who would have been eligible in the prospective-randomized studies that have shown that lung cancer screening reduces lung cancer mortality (NLST and NELSON), and to people meeting the criteria of the North American recommendations. The aim of the PREVALUNG ETOILE study is to set up and evaluate a lung cancer screening care pathway at the APHM, using a biological blood and faeces collection identical to that of PREVALUNG. PREVALUNG ETOILE plans to include 160 participants in 2023 (160 have already been included as of September 20, 2023). A 5-month follow-up after the first screening round is planned for each participant. The total number of participants to be included in Europe is 2750. The number of participants to be included in the French BIOCEPTION cohort will therefore be a maximum of 2,750. APHM is coordinating data collection from the various European centers involved in the PREVALUNG BIOCEPTION study. Pr Tatiana Kouznetsova of KU Leuven (Belgium) is in charge of the statistical analysis of the data, in collaboration with APHM.
The PREVALUNG BIOCEPTION cohort was set up to validate biomarkers of risk of incident lung cancer at 2 years, as part of screening. These biomarkers will subsequently serve as therapeutic targets for the primary prevention of lung cancer. As part of the PREVALUNG EU project, a prospective randomized 8-arm study is planned to demonstrate the biological effect of drug interventions on the 4 classes of biomarkers that will have been validated (see PREVALUNG EU appendix).
This protocol is therefore part of a scientifically validated project funded by the European Commission for the validation of biological biomarkers and the primary prevention of lung cancer risk in patients with smoking-related atheromatous disease. External validation of biomarkers from a cohort of participants at risk of lung cancer without atheromatous disease or moderate or severe calcium score (some participants of PREVALUNG ETOILE or newly recruited) will initiate the extension of the validation and application of these biomarkers to non-atheromatous populations.
Inclusion Criteria:
Inclusion criteria:
daily smoking for at least 10 years prior to disease (for smoking, there are no quantitative criteria or withdrawal times)
visual coronary calcium score quantified by a radiologist on a chest CT scan.
3- Individuals at risk of lung cancer without atheromatous disease or moderate or high calcium score being managed for a tobacco-related disease (chronic bronchitis or non-progressive cancer > 5 years) or with eligibility criteria for lung cancer screening (inclusion criteria in the NLST or NELSON studies or American recommendations)**.
Inclusion criteria :
and
- daily smoking for at least 10 years prior to the disease (for smoking, there are no quantitative criteria or withdrawal periods).
Or
Inclusion criteria in NLST :
NELSON inclusion criteria :
American recommendations :
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
COPD
Chronic obstructive pulmonary disease: long-term lung disease that makes it hard to breathe out, including emphysema and chronic bronchitis.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Diagnostic Test: blood sampling · Diagnostic Test: stool collection · Radiation: low dose CT scan
blood collection
stool collection
low dose CT scan evaluation
biomarker group validation
Sensitivity and specificity of each biomarker
Time frame: 51 months
Describe changes in biomarkers over time
reporting the value of each biomarker at each patient's visit to visit
Time frame: 51 months
Describe and compare biomarkers according to clinical characteristics of participants
Value of each biomarker according to the clinical characteristics of participants
Time frame: 51 months
Describe changes in quality of life over time
Quality of life (SF-12 score) at each visit.
Time frame: 51 months
Describe changes in smoking habits over time
Smoking cessation rate achieved (partial and/or total) among participants active smokers
Time frame: 51 months
Describe changes in anxiety over time
anxiety (STAI-YA and STAI-YB) at each visit.
Time frame: 51 months
Describe and compare biomarkers according to medical characteristics of participants
Value of each biomarkers according to medical characteristics of participants
Time frame: 51 months
Describe and compare biomarkers according to geographic characteristics of participants
Value of each biomarkers according to geographic characteristics of participants
Time frame: 51 months
Describe and compare biomarkers according to socioeconomic characteristics of participants
Value of each biomarkers according to socioeconomic characteristics of participants
Time frame: 51 months
Started Apr 2024 (actual). Primary completion is estimated for Jul 2028, 51 months after the start.
How these figures are worked out, and which studies are left out of them.
From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗
Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.
Contact study teamGet an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Assistance Publique Hopitaux De Marseille →